Results 61 to 70 of about 356,021 (162)

Galactose-Deficient IgA1 as a Candidate Urinary Polypeptide Marker of IgA Nephropathy? [PDF]

Disease Markers, 2016
In patients with IgA nephropathy (IgAN), circulatory IgA1 and IgA1 in mesangial deposits contain elevated amounts of galactose-deficient IgA1 (Gd-IgA1). We hypothesized that a fraction of Gd-IgA1 from the glomerular deposits and/or circulation may be excreted into the urine and thus represent a disease-specific biomarker.
Hitoshi Suzuki, Landino Allegri, Yusuke Suzuki, Stacy Hall, Zina Moldoveanu, Robert J. Wyatt, Jan Novak, Bruce A. Julian   +7 more
openaire   +2 more sources

Dotplot showing individual serum galactose deficient IgA1 values in all three groups.

, 2019
Dotplot showing individual serum galactose deficient IgA1 values in all three groups.
Geetika Singh (6519728), Raghavendra Lingaiah (6519722), Adarsh Barwad (6519725), Veena Balooni (316528), Sanjay Kumar Agarwal (6519734), Soumita Bagchi (6519719), Dipankar Bhowmik (6519731), Kalaivani Mani (316531)   +7 more
core   +1 more source

Using Synthetic Glycans to Investigate Anti‐Glycan Antibodies and Explore Their Medical Potential

Angewandte Chemie International Edition, Volume 65, Issue 39, 21 September 2026.
Anti‐glycan antibodies are essential in health and disease. Access to novel glycan structures paves the way for progress in antibody profiling for biomarker discovery, antibody development, and vaccine design. We summarize the strategies to synthesize and utilize synthetic glycans for the development and application of anti‐glycan antibodies in basic ...
Fabienne Weber, Aina Valenti, Jiří Ledvinka, Oren Moscovitz, Peter H. Seeberger   +4 more
wiley   +1 more source

Comparison of serum galactose deficient IgA1 levels between non-IgA glomerular disease subtypes and Iga nephropathy.

, 2019
Comparison of serum galactose deficient IgA1 levels between non-IgA glomerular disease subtypes and Iga nephropathy.
Geetika Singh (6519728), Raghavendra Lingaiah (6519722), Adarsh Barwad (6519725), Veena Balooni (316528), Sanjay Kumar Agarwal (6519734), Soumita Bagchi (6519719), Dipankar Bhowmik (6519731), Kalaivani Mani (316531)   +7 more
core   +1 more source

Sarsasapogenin Preserves Podocyte Integrity and Attenuates Renal Injury in Experimental IgA Nephropathy

The FASEB Journal, Volume 40, Issue 17, 15 September 2026.
Experimental IgA nephropathy leads to renal inflammation, fibrosis, podocyte injury, and impaired renal function. Sarsasapogenin treatment attenuated inflammatory and profibrotic signaling, reduced extracellular matrix accumulation, preserved nephrin and podocin expression, improved podocyte ultrastructure, and ameliorated renal histopathological ...
Meltem Kumaş, Dilek Canlar Akar, Mehmet Gül, Erkan Karadaş, Selen Kum Özşengezer, Kadri Kulualp, Orhan Yavuz, Osman Yilmaz   +7 more
wiley   +1 more source

Diagnostic potential of B‐cell translocation gene 2 in IgA nephropathy: Insights from molecular mechanisms

Journal of Cell Communication and Signaling, Volume 20, Issue 3, September 2026.
Diagnostic value of BTG2 and its immunoregulatory mechanism in IgAN. This study reveals that BTG2 improves immune microenvironment dysregulation, attenuates inflammation, and reduces fibrosis by promoting the expansion of T follicular helper cells, inducing macrophage polarization toward an M2 anti‐inflammatory phenotype, and inhibiting the TGF‐β1 ...
Min Kou, Mo Dan, Juan Cheng, Sheng Ge, Ruimin Ren   +4 more
wiley   +1 more source

A ROC curve of serum galactose deficient IgA1 level against IgA nephropathy patients and healthy controls 2B ROC cure of serum galactose deficienty IgA1 level against IgA nephropathy patients and non-IgA glomerular disease controls.

, 2019
A ROC curve of serum galactose deficient IgA1 level against IgA nephropathy patients and healthy controls 2B ROC cure of serum galactose deficienty IgA1 level against IgA nephropathy patients and non-IgA glomerular disease controls.
Geetika Singh (6519728), Raghavendra Lingaiah (6519722), Adarsh Barwad (6519725), Veena Balooni (316528), Sanjay Kumar Agarwal (6519734), Soumita Bagchi (6519719), Dipankar Bhowmik (6519731), Kalaivani Mani (316531)   +7 more
core   +1 more source

Galactose‐Deficient Immunoglobulin A1 Predicts Immunoglobulin A Nephropathy Recurrence After Kidney Transplantation: A Single‐Center Retrospective Study

Organ Medicine, Volume 3, Issue 3, Page 139-147, September 2026.
Serum galactose‐deficient IgA1 levels at 3 and 6 months predicted recurrent IgA nephropathy after kidney transplantation. Recipients without recurrence showed a rapid decline in galactose‐deficient IgA1 after transplantation. Early identification of recurrence risk provided a potential window for targeted post‐transplant intervention.
Ronghai Deng, Wengen Chen, Xinhua Chang, Zehuan Chen, Qianyu Ye, Bowen Xu, Yifang Gao, Suxiong Deng, Xiaolin Yu, Changxi Wang, Xiangjun Liu   +10 more
wiley   +1 more source

Diagnosis and treatment of patients with IgA nephropathy in Japan

Kidney Research and Clinical Practice, 2016
Chronic kidney disease (CKD) is a worldwide public health problem that affects millions of people from all racial and ethnic groups. Although CKD is not one specific disease, it is a comprehensive syndrome that includes IgA nephropathy.
Yasuhiko Tomino
doaj   +1 more source

Significance of serum galactose deficient IgA1 as a potential biomarker for IgA nephropathy: A case control study - Fig 4

, 2019
Histogram showing distribution of values of serum galactose deficient IgA1(ng/ml) before(4A) and after(4B) logarithmic transformation.
Geetika Singh (6519728), Raghavendra Lingaiah (6519722), Adarsh Barwad (6519725), Veena Balooni (316528), Sanjay Kumar Agarwal (6519734), Soumita Bagchi (6519719), Dipankar Bhowmik (6519731), Kalaivani Mani (316531)   +7 more
core   +1 more source